The Dana-Farber Cancer Institute (DFCI) offers a 1-year post graduate residency program focuses on advance training in medication-use safety, drug policy, and quality assessment. The program provides various opportunities designed to develop the resident’s skill in formulary management, policy development, leadership, medication safety principles, and quality improvement.
By actively participating in medication error, pharmacy, and adverse drug event reporting processes, the PGY2 Medication-Use Safety Pharmacy Resident will gain experience in medication safety assessment as well as quality and process improvement. The resident will participate in several medication safety-related activities, such as root cause analyses, system assessments, and quality/process improvement projects. The resident will also lead the interdisciplinary pharmacy intervention subcommittee, serve as a member of the ambulatory event committee, pharmacy and therapeutics committee, and will partake in various clinical informatics workgroups. Other activities may include conducting pharmacy safety rounds, policy and guideline development, and workflow development and implementation. All the while, promoting a culture of safety within the department and across the institute. The resident will foster these skills in the outpatient, inpatient, adult, pediatric and investigational drug service settings.
The Resident will work closely with other interdisciplinary departments including the Center of Patient Safety, Risk Management, Quality/Process Improvement, Clinical Informatics, among others. There is also an opportunity to complete an away rotation at the Institute for Safe Medication Practices (ISMP).
The fundamental goal of the residency is to provide training so that pharmacists develop excellent knowledge in the principles of medication-use safety; communication and leadership; strategies to collect, analyze and implement changes to clinical and operational processes which promote safe medication-use practices. While the primary focus of this PGY2 is medication use safety and policy, there is an oncology clinical component as well. The oncology clinical training may be customized to the resident’s interest.
Applicants must expect to complete an ASHP accredited PGY-1 pharmacy residency and be licensed in the state of Massachusetts by summer of 2019. Application requirements: Complete PhORCAS application by Tuesday, January 3, 2023.
PPS interviews will be conducted on Sunday, December 4th through Wednesday December 7th. For consideration for an interview, please send a message through the PPS messenger. Priority will be given to candidates who submit interview requests by Friday, November 18th.
Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world.
The mission of the Dana-Farber Cancer Institute Pharmacy Department is to provide expert pharmaceutical care to our patients as an integral member of the health care team. The Pharmacy Department also provides clinical and technical training to pharmacy students and pharmacy residents.